Medical and Pharmaceutical Innovent Biologics secures 2nd NDA approval for lung cancer drug as 1st-line treatment China's National Medical Products Administration approved the initial new drug application in January Rowan DunneApril 25, 2025
Medical and Pharmaceutical Innovent and ASK Pharm scoop Chinese regulator approval for oral lung cancer drug 'Limertinib' targets non-small cell lung cancer with a particular mutation that is prevalent in Asian patients Rowan DunneJanuary 17, 2025
Medical and Pharmaceutical Roche secures rights to Chinese biotech company’s small cell lung cancer drug Innovent Biologics will receive up to US$1 billion in milestone payments and royalties Rowan DunneJanuary 3, 2025